Wednesday, March 24, 2021 3:04:41 AM
Number Steven / Kiwi
Why did Amarin not bring Rule 60 ?
Examine -possible explanations
1-They have been advised it has absolutely no possibility of success -
comment -
whilst the basis of the Rule 60 application has taken time to develop and was perhaps therefore not immediately apparent in the aftermath of the Du decision one only needs to read the documentation now produced by Marjac and the team to reach the conclusion that the application was worth making - on any view it has some chance of success
So it is hard to believe Amarin and it’s lawyers were jointly of the view it had zero merit
2-They consider a Rule 60 directly conflicts with their other legal initiatives
Comment -
Infringement action -hard to see any basis upon which there can be any conflict so that Rule 60 diminishes in any way this initiative
Perhaps they consider success here is guaranteed and only Ten per cent of the USA market will be at risk and that such is uneconomic for sustainable GV - big balls to reach this conclusion and to abandon other initiatives??
3-Appeal against Du decision
Comment - the SC application it has been suggested has now no more than 1 percent chance of success ...so low that it would hardly persuade to abandon other initiatives- it may have been felt that at FC stage a higher hope existed and that was the horse they wished to back - again however difficult to see conflict between appeal lines of argument and Rule 60
With a current 1 percent chance of Supreme court success you only have to give Rule 60 1 percent chance to consider it equally worthy so why not bring such an action?
4-They considered bringing Rule 60 exposes Amarin and it’s lawyers to critical examination as to their conduct of the Du trial -which may lead to legal class action being brought against them
Do I need to comment ???
5-They are simply totally incompetent and never thought of doing it nor did their lawyers
Comment
Each of us will have our own view of their competency
Any other reasons ??? None immediately come to mind
Alm
Why did Amarin not bring Rule 60 ?
Examine -possible explanations
1-They have been advised it has absolutely no possibility of success -
comment -
whilst the basis of the Rule 60 application has taken time to develop and was perhaps therefore not immediately apparent in the aftermath of the Du decision one only needs to read the documentation now produced by Marjac and the team to reach the conclusion that the application was worth making - on any view it has some chance of success
So it is hard to believe Amarin and it’s lawyers were jointly of the view it had zero merit
2-They consider a Rule 60 directly conflicts with their other legal initiatives
Comment -
Infringement action -hard to see any basis upon which there can be any conflict so that Rule 60 diminishes in any way this initiative
Perhaps they consider success here is guaranteed and only Ten per cent of the USA market will be at risk and that such is uneconomic for sustainable GV - big balls to reach this conclusion and to abandon other initiatives??
3-Appeal against Du decision
Comment - the SC application it has been suggested has now no more than 1 percent chance of success ...so low that it would hardly persuade to abandon other initiatives- it may have been felt that at FC stage a higher hope existed and that was the horse they wished to back - again however difficult to see conflict between appeal lines of argument and Rule 60
With a current 1 percent chance of Supreme court success you only have to give Rule 60 1 percent chance to consider it equally worthy so why not bring such an action?
4-They considered bringing Rule 60 exposes Amarin and it’s lawyers to critical examination as to their conduct of the Du trial -which may lead to legal class action being brought against them
Do I need to comment ???
5-They are simply totally incompetent and never thought of doing it nor did their lawyers
Comment
Each of us will have our own view of their competency
Any other reasons ??? None immediately come to mind
Alm
Recent AMRN News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 08:30:11 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 03/30/2026 09:57:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/27/2026 09:00:07 PM
- Amarin Highlights Guideline Recommended Role of Icosapent Ethyl in Managing Cardiovascular Risk Following Release of Updated 2026 ACC/AHA/Multisociety Dyslipidemia Guideline • GlobeNewswire Inc. • 03/18/2026 12:30:00 PM
- New REDUCE-IT Data in Patients at Extreme Cardiovascular Risk and In Vitro Research on the Mechanistic Effects of Eicosapentaenoic Acid (EPA) on Lipoprotein(a) [Lp(a)] Oxidation to be Presented at the American College of Cardiology’s (ACC) Annual Scienti • GlobeNewswire Inc. • 03/16/2026 12:15:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/02/2026 10:31:01 PM
- Effects of Icosapent Ethyl on Risk and Duration of Hospitalizations and Death in REDUCE-IT® Post Hoc Analysis Published in the European Journal of Preventive Cardiology • GlobeNewswire Inc. • 03/02/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 12:05:26 PM
- Amarin Reports Fourth Quarter and Full Year 2025 Financial Results • GlobeNewswire Inc. • 02/25/2026 12:00:00 PM
- This American Heart Month Amarin Spotlights the Need to Prioritize Proven Widely Available Yet Underutilized Therapies in the Battle Against Cardiovascular Disease • GlobeNewswire Inc. • 02/23/2026 01:00:00 PM
- Amarin to Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on February 25, 2026 • GlobeNewswire Inc. • 02/11/2026 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:09 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:07 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:06 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:05 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:04 AM
- Amarin Applauds Breakthroughs In Therapies For Patients With Elevated Triglycerides; Company’s VASCEPA®/VAZKEPA® (Icosapent Ethyl) Franchise Well Positioned To Benefit Globally From Broadened Category Commercialization • GlobeNewswire Inc. • 01/09/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/08/2026 12:05:27 PM
- Amarin Announces Preliminary 2025 Financial Highlights and Operational Accomplishments, Including Achieving Positive Cash Flow; Company Well Positioned to Capture Global Growth Opportunities • GlobeNewswire Inc. • 01/08/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2026 10:00:21 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2026 10:00:17 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2026 10:00:10 PM
- New REDUCE-IT® Aspirin Analysis Presented at AHA Scientific Sessions 2025 Reinforces VASCEPA®/VAZKEPA® (Icosapent Ethyl) Reduced Cardiovascular Events in High-Risk Patients • GlobeNewswire Inc. • 11/09/2025 09:15:00 PM
- Amarin To Present New Analyses Affirming Robustness of Data from REDUCE-IT and Additional Mechanisms of Action of Eicosapentaenoic Acid (EPA) at American Heart Association (AHA) Scientific Sessions 2025 • GlobeNewswire Inc. • 11/03/2025 01:30:00 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 10/31/2025 08:30:06 PM
